Jinsong Liu Selected Research

Phosphotransferases (Kinase)

10/2022	Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.
1/2017	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.
6/2009	Biological significance of prolactin in gynecologic cancers.
11/2006	A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas.
6/2006	Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
5/2004	Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jinsong Liu Research Topics

Disease

184	Neoplasms (Cancer) 04/2024 - 08/2002
84	Ovarian Neoplasms (Ovarian Cancer) 01/2024 - 03/2003
40	Carcinoma (Carcinomatosis) 03/2022 - 09/2003
28	Carcinogenesis 10/2023 - 03/2003
15	Neoplasm Metastasis (Metastasis) 12/2022 - 07/2006
12	Ovarian Epithelial Carcinoma 12/2023 - 02/2004
12	Breast Neoplasms (Breast Cancer) 01/2023 - 09/2003
11	Infections 01/2024 - 08/2003
8	Endometrioid Carcinoma 06/2011 - 10/2003
6	Polyploidy 01/2023 - 06/2013
6	Insulin Resistance 06/2022 - 04/2008
5	Osteoporosis 04/2022 - 12/2014
5	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 10/2006
5	Lung Neoplasms (Lung Cancer) 01/2017 - 06/2009
5	Ascites 03/2012 - 03/2004
4	Genomic Instability 04/2024 - 06/2010
4	Hypoxia (Hypoxemia) 11/2023 - 02/2007
4	Adenocarcinoma 01/2022 - 10/2006
4	Endometrial Neoplasms (Endometrial Cancer) 12/2021 - 07/2006
4	Cystadenoma 01/2014 - 10/2004
4	Microsatellite Instability 11/2006 - 10/2003
3	COVID-19 03/2024 - 10/2022
3	Inflammation (Inflammations) 02/2024 - 09/2020
3	Diarrhea 01/2024 - 02/2009
3	Colonic Neoplasms (Colon Cancer) 10/2023 - 08/2017
3	Parkinson Disease (Parkinson's Disease) 12/2022 - 01/2019
3	Weight Loss (Weight Reduction) 09/2022 - 08/2019
3	AIDS-Related Complex (ARC) 04/2022 - 01/2014
3	Weight Gain 01/2022 - 04/2008
3	Bone Resorption 11/2021 - 12/2014
3	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2015 - 01/2008
3	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2014 - 09/2003

Drug/Important Bio-Agent (IBA)

54	Proteins (Proteins, Gene)FDA Link 05/2024 - 08/2003
18	Messenger RNA (mRNA)IBA 10/2023 - 02/2004
18	Small Interfering RNA (siRNA)IBA 01/2018 - 08/2003
13	Biomarkers (Surrogate Marker)IBA 12/2023 - 11/2005
11	Paclitaxel (Taxol)FDA LinkGeneric 09/2021 - 04/2003
10	CytokinesIBA 02/2024 - 03/2004
8	MicroRNAs (MicroRNA)IBA 05/2023 - 01/2011
8	Estrogens (Estrogen)FDA Link 06/2022 - 04/2003
7	AntioxidantsIBA 01/2024 - 03/2004
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 02/2004
7	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2008 - 03/2003
6	Interleukin-6 (Interleukin 6)IBA 01/2024 - 03/2004
6	EnzymesIBA 01/2024 - 03/2004
6	RNA (Ribonucleic Acid)IBA 10/2023 - 08/2003
6	Phosphotransferases (Kinase)IBA 10/2022 - 05/2004
6	LigandsIBA 01/2022 - 11/2004
6	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 04/2003
6	Peptides (Polypeptides)IBA 01/2021 - 11/2004
6	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 11/2004
5	AntigensIBA 01/2024 - 11/2005
5	AntibodiesIBA 10/2022 - 03/2004
5	LipidsIBA 06/2022 - 07/2008
5	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2022 - 03/2004
5	Estrogen ReceptorsIBA 01/2021 - 07/2004
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021 - 02/2013
5	Keratins (Keratin)IBA 11/2019 - 06/2003
5	Cisplatin (Platino)FDA LinkGeneric 07/2016 - 10/2005
5	NF-kappa B (NF-kB)IBA 01/2016 - 03/2004
5	Transcription Factors (Transcription Factor)IBA 08/2015 - 04/2006
5	Antineoplastic Agents (Antineoplastics)IBA 01/2015 - 09/2008
5	ErbB Receptors (EGF Receptor)IBA 11/2012 - 12/2006
5	Hormones (Hormone)IBA 01/2011 - 01/2007
4	Antiviral Agents (Antivirals)IBA 03/2024 - 01/2022
4	InterleukinsIBA 01/2024 - 03/2004
4	TitaniumIBA 04/2022 - 01/2014
4	ChemokinesIBA 01/2021 - 10/2006
4	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 12/2008
4	Phenobarbital (Luminal)FDA Link 01/2021 - 07/2006
4	Interleukin-8 (Interleukin 8)IBA 01/2021 - 03/2004
4	CalciumIBA 06/2017 - 12/2005
4	Cyclin-Dependent Kinase Inhibitor p16IBA 03/2017 - 10/2006
4	ras ProteinsIBA 02/2009 - 08/2003
4	ParaffinIBA 01/2008 - 06/2003
4	Cyclin D1IBA 01/2006 - 10/2002
3	Immunoglobulins (Immunoglobulin)IBA 01/2024 - 01/2021
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 10/2017
3	PlatinumIBA 10/2022 - 01/2015
3	Volatile Fatty AcidsIBA 06/2022 - 01/2021
3	Capsules (Microcapsules)IBA 06/2022 - 07/2006
3	Monoamine Oxidase (MAO)IBA 04/2022 - 01/2014
3	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 05/2004
3	ProlactinIBA 01/2020 - 06/2009
3	lysophosphatidic acidIBA 01/2019 - 08/2004
3	Inhibins (Inhibin)IBA 08/2017 - 06/2003
3	Mitogen-Activated Protein KinasesIBA 01/2016 - 06/2009
3	Focal Adhesion Protein-Tyrosine KinasesIBA 10/2013 - 12/2005
3	Indicators and Reagents (Reagents)IBA 06/2013 - 05/2006
3	Tumor Suppressor Protein p14ARF (p14ARF)IBA 06/2012 - 10/2006
3	Aurora Kinase AIBA 02/2012 - 06/2010
3	AndrogensIBA 01/2011 - 03/2005
3	Progesterone FDA LinkGeneric 01/2011 - 03/2005
3	beta CateninIBA 01/2010 - 10/2005

Therapy/Procedure

51	Therapeutics 04/2024 - 04/2003
25	Drug Therapy (Chemotherapy) 11/2023 - 04/2003
6	Neoadjuvant Therapy 11/2023 - 01/2015
5	Immunotherapy 10/2023 - 01/2007
4	Radiotherapy 01/2021 - 10/2005
3	Laparotomy 10/2018 - 08/2002